What is he best known for?
The fields of study he is best known for:
Aptamer, RNA, Molecular biology, Gene and Cell biology are his primary areas of study.
His Aptamer research integrates issues from In vitro, Small molecule, Antibody, Computational biology and Pharmacology.
His Pharmacology research is multidisciplinary, relying on both Anticoagulant, Aptamer Technology and Factor IXa.
The various areas that Bruce A. Sullenger examines in his RNA study include Nucleic acid and DNA.
His biological study spans a wide range of topics, including Cell culture and Transfection.
His study in Cell biology is interdisciplinary in nature, drawing from both Agonist, Receptor, Cell and Glioma.
His most cited work include:
- Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. (823 citations)
- Aptamers: An Emerging Class of Therapeutics (758 citations)
- In vivo activity of nuclease-resistant siRNAs (502 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Aptamer, RNA, Molecular biology, Cell biology and Biochemistry.
His Aptamer research is multidisciplinary, incorporating perspectives in Oligonucleotide, Systematic evolution of ligands by exponential enrichment, Pharmacology, Computational biology and Thrombin.
In his research on the topic of Pharmacology, Heparin is strongly related with Anticoagulant.
His RNA study integrates concerns from other disciplines, such as DNA and Intron.
His Molecular biology study incorporates themes from Cell, Integrin, Cancer research, In vitro and Transfection.
His study ties his expertise on Receptor together with the subject of Cell biology.
He most often published in these fields:
- Aptamer (41.37%)
- RNA (26.91%)
- Molecular biology (25.70%)
What were the highlights of his more recent work (between 2017-2021)?
- Aptamer (41.37%)
- Cancer research (14.46%)
- Nucleic acid (15.66%)
In recent papers he was focusing on the following fields of study:
Bruce A. Sullenger mainly investigates Aptamer, Cancer research, Nucleic acid, Cell biology and Cancer.
The study incorporates disciplines such as Anticoagulant, Antibody, Pharmacology and Systematic evolution of ligands by exponential enrichment in addition to Aptamer.
The concepts of his Cancer research study are interwoven with issues in Pancreatic cancer, Cancer cell, Metastasis, Triple-negative breast cancer and Prostate cancer.
Bruce A. Sullenger has researched Cell biology in several fields, including Native state, Reprogramming, Oligonucleotide and RNA.
His RNA research integrates issues from Interferon, Nucleotide and Programmed cell death.
The study incorporates disciplines such as Transfection and Transactivation in addition to Cancer.
Between 2017 and 2021, his most popular works were:
- Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer (35 citations)
- Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers (25 citations)
- Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass. (21 citations)
In his most recent research, the most cited papers focused on:
His primary areas of investigation include Aptamer, Pharmacology, Antibody, Anticoagulant and Oligonucleotide.
His Aptamer research is multidisciplinary, relying on both Epidermal growth factor receptor, Heparin, Native state, Cell biology and Cell sorting.
His Transcription research extends to Pharmacology, which is thematically connected.
His studies in Anticoagulant integrate themes in fields like Hemostasis, Coagulation and Bioinformatics.
His work in Oligonucleotide tackles topics such as Computational biology which are related to areas like Nucleic acid.
His studies deal with areas such as Pancreatic cancer, Cancer cell, RNA, Extracellular and Tumor progression as well as Nucleic acid.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
